Bipolar Disorder Clinical Trial
Official title:
Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms
The purpose of this study is to determine whether gamma-Hydroxybutyrate (GHB) has prosocial and prosexual effects in healthy male participants, and to characterize these putative effects via behavioral tests, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and neuroendocrine parameters. The investigators predict that GHB in fact has prosocial and prosexual effects which can be neurobiologically characterized using the assessed methods. Such effects would be of high interest for the treatment of mental disorders which involve impairments of social interaction and sexual function such as major depression or autism.
Introduction
Gammahydroxybutyrate (GHB) is an endogenous short-chain fatty acid and discussed as a
neurotransmitter (Bessman and Fishbein, 1963) with high affinity to specific GHB (Benavides
et al., 1982; Snead, 2000) and α4βδ-gamma-Aminobutyric acid (GABA)A receptors (Absalom et
al., 2012) that also binds with lower affinity to GABAB receptors (Engberg and Nissbrandt,
1993). It is internationally used as standard treatment for narcolepsy with cataplexy
(Alshaikh et al., 2012), and in some European countries for alcohol withdrawal and craving
(Keating, 2014). Additionally, recent randomized controlled studies showed therapeutic
effects in fibromyalgia (Spaeth et al., 2013). Anecdotal reports from GHB abusers indicate
mood enhancing, prosocial and prosexual effects of the drug (Sumnall et al., 2008), which
were not objectively assessed so far. Impaired social decision making is a behavioral finding
in depression (Pulcu et al., 2014), that is related to social withdrawal symptoms. Moreover,
sexual dysfunction is both a symptom of depression and an adverse effect of most
antidepressant medications (Kennedy and Rizvi, 2009), with a deteriorating impact on quality
of life measures. Due to its unique pharmacologic effects on sleep, daytime vigilance, pain,
and social interaction, GHB was recently proposed as experimental therapeutic for the
treatment of depression (Bosch et al., 2012).
Study Aims
A) Investigating the putative prosocial effects of GHB in humans B) Investigating the
putative prosexual effects of GHB in humans C) Investigating the neuroendocrine mechanisms of
putative prosocial and prosexual effects of GHB in humans D) Investigating
electrophysiological effects of GHB in decision-making in humans E) Investigating the
functional neurobiology of GHB and its putative prosexual effects in humans
Study Design
A) The effects of GHB on social cognition, sexual arousal, neuroendocrine parameters, and EEG
measures in healthy subjects: GHB (20 mg/kg p.o.) was tested in 16 healthy males, using a
randomized, placebo-controlled, cross-over design. Subjective effects on mood were assessed
by visual analogue scales (VAS) and the GHB Specific Questionnaire (GSQ). Prosocial behavior
was examined by the Charity Donation Task, the Social Value Orientation test, and the
Reciprocity Task. We assessed reaction time and motor performance using the Delayed Matching
to Sample and the Reaction Time tasks from the Cambridge Neuropsychological Test Automated
Battery (CANTAB). We assessed social cognition using the Multifaceted Empathy Task (MET) and
the Movie for the Assessment of Social Cognition (MASC). We assessed memory using a German
version of the Rey Auditory Verbal Learing Task. Sexual arousal was assessed using the Sexual
Arousal and Desire Inventory (SADI), sexual perception was assessed using a self-designed
Sexual Arousal Task (SAT). Furthermore, the investigators assessed GHB effects on brain
electrophysiological activity using electroencephalography (EEG) and a flanker task for the
assessment of error-related negativity. Blood plasma levels of GHB, oxytocin, testosterone,
progesterone, dehydroepiandrosterone (DHEA), cortisol, aldosterone, and adrenocorticotropic
hormone (ACTH) were determined.
B) The effects of GHB on neuronal networks and sexual arousal in healthy subjects - an fMRI
study: The investigators performed a characterization of the putative prosexual effects of
GHB (35 mg/kg vs. placebo p.o.) in 19 healthy participants. Questionnaires (VAS, SADI, GSQ)
were used to assess subjective aspects. Brain reactivity towards erotic vs. neutral pictures
of persons, as well as resting state connectivity and arterial spin labelling (ASL) was
investigated with functional magnetic resonance imaging (fMRI).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |